Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
Berger
Joseph R
JR
Centonze
Diego
D
Comi
Giancarlo
G
Confavreux
Christian
C
Cutter
Gary
G
Giovannoni
Gavin
G
Gold
Ralf
R
Hartung
Hans-Peter
HP
Lublin
Fred
F
Miravalle
Augusto
A
Montalban
Xavier
X
O'Connor
Paul
P
Olsson
Tomas
T
Polman
Chris H
CH
Stuve
Olaf
O
Wolinsky
Jerry S
JS
Ziemssen
Tjalf
T
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab